Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P2KG
|
||||
| Former ID |
DCL000404
|
||||
| Drug Name |
GSK1144814
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Discontinued in Phase 1 | [1] | ||
| Company |
GSK
|
||||
| Target and Pathway | |||||
| Target(s) | Nigral tachykinin NK(3) receptor | Target Info | Modulator | ||
| Substance-P receptor | Target Info | Modulator | |||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Measles | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling eventsR-HSA-416476:G alpha (q) signalling events | ||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| Spinal Cord Injury | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01090440) Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.